New cocktail therapy hopes to tackle tough lung cancer
NCT ID NCT03381274
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests two new drug combinations in people with advanced EGFR-mutated non-small cell lung cancer whose previous treatments have stopped working. The study combines a biologic (oleclumab) with either the targeted drug osimertinib or another experimental drug (AZD4635). The main goals are to check safety and see if the tumors shrink. About 43 adults are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Oleclumab (a biologic) combined with either osimertinib (Tagrisso) or AZD4635 (a drug)
What this could lead to
If successful, this could point toward new combination treatments that help control advanced EGFR-mutated lung cancer after other therapies stop working.
What could go wrong
This is an early-phase trial with only 43 participants, so results may not apply to all patients. The combinations may cause serious side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
San Francisco, California, 94143, United States
-
Research Site
Aurora, Colorado, 80045, United States
-
Research Site
New Haven, Connecticut, 06510, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Baltimore, Maryland, 21224, United States
-
Research Site
New York, New York, 10032, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Taichung, 40705, Taiwan